Wang et al.’s [95] results showed that the Neuropilin-2 (NRP2), which functions as a VEGF receptor on tumour cells, is an attractive target to activate antitumor immunity in prostate cancer because VEGF-NRP2 signalling sustains PD-L1 expression. Here, NRP2 is linked to neoplasm.